Daewoong Pharmaceutical's Nabota has secured regulatory approval in Kuwait, marking its seventh Middle Eastern market entry. The expansion completes the company's sweep across the Gulf Cooperation Council region—a strategic move that positions the Korean botulinum toxin as a credible alternative to Allergan Aesthetics' Botox and Galderma's Dysport in one of the world's highest-spending aesthetic markets.
Market
Daewoong's Nabota Enters Kuwait—7th Middle East Market
South Korean toxin completes GCC footprint, signaling aggressive regional strategy beyond AbbVie and Galderma.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Nabota now reaches all seven major GCC markets—a footprint that rivals established toxin players in the region.
Nabota's Middle East penetration reflects Daewoong's disciplined international playbook: establish presence in high-income markets where toxin adoption is mature and price-sensitive buyers seek alternatives. Kuwait's affluent demographic and established aesthetic infrastructure make it a logical addition. The cumulative effect of seven-market coverage signals that Nabota is transitioning from niche player to regional competitor, with the scale to negotiate rebate programs and secure shelf space in multi-modality clinics.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.